Navigation Links
Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors
Date:2/15/2013

MUMBAI, February 15, 2013 /PRNewswire/ --

Bharatbook.com is pleased to announce a new research report on Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors (http://www.bharatbook.com/healthcare-market-research-reports/drivers-of-m-a-in-2013-2016-pi3ks-and-btk-inhibitors.html)

New targets/drugs remain an evergreen medical need to address the unmet need of drug resistance in the treatment of cancer. Large global pharma are constantly on the hunt for drugs with label expansion potential = Longevity and Blockbuster Potential! About $10b+ has already been invested in licensing /acquisition of PI3K and other kinase inhibitors/companies since the last five years. Scientific data on the role of PI3K, BTK kinase in cancer and clinical Proof of Concept (PoC) data of the PI3K, BTKs inhibitors have reached a critical mass and companies with focus in this sector are poised to offer better treatment options for unmet need in hematologic malignancies. We expect more acquisitions of the innovator companies and or handsome licensing deals for unpartnered products as mature data and approvals come in the next few years. This report highlights the recent progress on the understanding of PI3Ks/BTK signaling pathway and companies developing PI3K/BTK inhibitors, the clinical data and competition.

     (Logo: http://photos.prnewswire.com/prnh/20130128/590935)

Key Points Discussed in the Report

  • Drugs in the pipeline

PI3K inhibitors - Infinity pharma (INFI), Gilead (GILD)

Dual PI3K inhibitor - Onconova/SymBio, Curis (CRIS)

BTK-inhibitors - Safety and clinical efficacy set it apart - Pharmacyclics (PCYC), Celgene (CELG)

  • M&A in Kinase Inhibitors in the last 5 years
  • Related Milestones/catalysts in 2013-14
  • Combination Studies - PI3K, BTK inhibitors with Rituxan, Bendamustine in hematological cancers.
  • Ongoing Clinical Trials of Companies Covered
  • Detailed reports on

SymBio pharma (4582, ¥488)

Curis (CRIS, $2.99)

Gilead (GILD, $40.36)

Pharmacyclics (PCYC, $69.28) -

Infinity pharma (INFI, $35.02)

Request for Sample pages - http://www.bharatbook.com/RequestSample.asp?pid=372901

Table of Contents

Executive Summary

Drugs in the Pipeline

Phosphoinositide 3-Kinases (PI3Ks) inhibitors

Scientific Rationale

Dual inhibitors

Bruton's Tyrosin Kinase (BTK) Inhibitors

Scientific Rationale

BTK inhibitors - Pipeline

M&A to Follow - Kinase inhibitors have attracted partnering deals at a premium

Kinase Inhibitor: Select M&A / Deals

Upcoming Milestones Related in 2013-14

Combination Studies - PI3K, BTK + Rituxan/ Bendamustine

Idelalisib (GS-1101) - Clinical Data

Rigosertib - Clinical Data

Other PI3K or Dual Inhibitors - Clinical Data

Combination Studies of PI3K and BTK Inhibitors

Ongoing Trials of PI3K and BTK Compounds

Company Analysis

Curis (CRIS) -

Gilead -

Infinity Pharma

Pharmacyclics

SymBio

Get an overview of the report at or request for sample pages at -

http://www.bharatbook.com/healthcare-market-research-reports/drivers-of-m-a-in-2013-2016-pi3ks-and-btk-inhibitors.html

For Complete range of Related Reports:

About Bharat Book Bureau

Bharat Book Bureau is the leading market research information aggregator that provides market research reports, industry analysis, company profiles, business reports, country reports, newsletters and online databases. Our clients include Corporate, Consulting firms, and Academic Institutions and Government departments across the globe. Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. The market research reports we provide, help global companies examine the different markets before setting up a business or expanding into different countries across the world. They give a complete perspective on the current market scenario, trends, segments and future outlook.

Contact us:
Maria
Bharat Book Bureau
India: +91-22-27810772, 27810773
USA/Canada - 1-866-279-8368 (Toll free)
Skype - bharatbook
E-mail: maria@bharatbook.com
Website: http://www.bharatbook.com


'/>"/>
SOURCE Bharat Book Bureau
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Womens Health Expert GC-Rise Ties up with Georgetown MBA Team to Tap M&A Potential and Growth Strategy
2. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
3. Kinase Inhibitors: Global Markets -- Focus on the U.S.
4. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
5. Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
6. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... any gene in its endogenous context, enabling overexpression experiments and avoiding the use ... with small RNA guides is transformative for performing systematic gain-of-function studies. , ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life Sciences ... the life sciences and healthcare industries, announces a presentation by Subbu Viswanathan and ... presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach ...
Breaking Biology Technology:
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
Breaking Biology News(10 mins):